Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?

BACKGROUND: Reliable evaluation of treatment benefit in early phase clinical trials is necessary. The time to progression ratio (TTPr), which compares successive TTP in a single patient, is a powerful criteria for determining targeted or immune therapies efficacy. METHODS: We evaluated 205 TTPr in a...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Br J Cancer
Asıl Yazarlar: Watson, Sarah, Menis, Jessica, Baldini, Capucine, Martin-Romano, Patricia, Michot, Jean-Marie, Hollebecque, Antoine, Armand, Jean-Pierre, Massard, Christophe, Soria, Jean-Charles, Postel-Vinay, Sophie, Paoletti, Xavier
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group UK 2018
Konular:
Brief Communication
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6203755/
https://ncbi.nlm.nih.gov/pubmed/30327567
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0245-0
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller